Our Team
About Us Submenu
Dr. Janessa Laskin, MD
Dr. Laskin is at the forefront of precision oncology, working to implement cancer genomics into treatment planning for cancer patients. Medical oncologist and clinical researcher Dr. Janessa Laskin has been at the forefront of BC Cancer’s Personalized OncoGenomics (POG) program since before it even began. She had her first glimpse of the power of genomics for cancer patient care when, in 2008, she worked closely with scientists the GSC to conduct whole genome and transcriptome analyses for one of her patients, enabling her to design a personalized therapeutic strategy. In 2010, their findings were published in the first study of its kind, demonstrating the use of whole genome and transcriptome analyses to inform therapeutic decisions.
Dr. Laskin did her medical training at UBC and BC Cancer. Following a Fellowship at Vanderbilt University, she returned to Vancouver in 2003 where she is now a Clinical Associate Professor of Medicine in the Division of Medical Oncology through UBC and BC Cancer. In her role, Dr. Laskin is heavily engaged in clinical and translational research. As co-Founder and Clinical Lead of the POG program, she works with an interdisciplinary team of oncologists, pathologists, medical geneticists, interventional radiologists and surgeons to revolutionize our understanding of the use of genomics for cancer treatment planning.
Dr. Marco Marra, OC, OBC, PhD, FRS(C), FCAHS, LLD (hon), DSc (hon)
Dr. Marra is a UBC Professor of Medical Genetics and the Michael Smith Laboratories. Formerly Head of Medical Genetics (UBC) and co-founder and past Director of Canada’s Michael Smith Genome Sciences Centre for more than two decades, Dr. Marra is known for his work in genomics and precision cancer genomic medicine.
Dr. Marra earned BSc and PhD degrees from SFU. During a post-doctoral fellowship in St. Louis, working on the Human Genome Project, Dr. Marra devised approaches to build sequence-ready maps of the human genome and led the team that created the map, fueling the production of the human genome sequence. Dr. Marra was recruited to Vancouver by Nobel Laureate Dr. Michael Smith, where he led teams that contributed to sequencing model organism genomes.
From Vancouver, Dr. Marra sought to drive the expansion of genomics in Canada. Dr. Marra led or co-led numerous cancer projects, revealing new mutations, biomarkers, and therapeutic targets in ovarian cancers, B cell lymphomas, brain cancers, breast cancers, medulloblastomas, leukemias, rhabdoid tumours and cervical cancers. In 2003, he led the effort that generated the first sequence of the agent causing SARS, revealing it to be a coronavirus and demonstrating that genome sequencing of a pathogen could be a key part of a rapid response to an emerging infectious disease. Dr. Marra currently co-leads the first program to demonstrate the use of whole genome and transcriptome sequencing to personalize cancer medicine. The program team, including 80% of the medical oncologists in BC, recruited 2,000 patients with advanced cancer and published >50 manuscripts describing how whole genome and transcriptome sequencing can influence clinical treatment decision making to bring benefit to cancer patients and their families.
A committed educator, Dr. Marra co-founded, co-directed and co-funded UBC’s Genome Sciences and Technology Graduate Program and was a founding member of the Bioinformatics Program. These programs have graduated hundreds of students, establishing BC as a nexus for advanced genomics and bioinformatics training.
Dr. Alannah Smrke, MD, FRCPC
Dr. Alannah Smrke (she/her) treats sarcoma and gynecological cancers. She completed her training at McMaster University and the University of British Columbia. She completed a fellowship in Sarcoma at The Royal Marsden Hospital in London, UK. She is interested in precision oncology, treatment of rare tumours and adolescent and young adult oncology.
Dr. Daniel Renouf MD, MPH, FRCPC
Daniel Renouf is a medical oncologist at the British Columbia Cancer Agency, Vancouver Centre, and an Assistant Professor at the University of British Columbia, Department of Medicine. He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and British Columbia Cancer Agency. He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto, and obtained a Masters of Public Health from Harvard University.
Daniel’s research interests include developmental therapeutics, genomics, and biomarker development within gastrointestinal cancers, with a focus on pancreatic cancer. He is the leader of the BC Cancer Agency Phase I program, the Co-Director of Pancreas Centre BC and is the Co-chair of the NCIC pancreatic cancer disease group.
Dr. Howard Lim, MD, FRCPC, PhD
Howard Lim, a Clinical Associate Professor with the Faculty of Medicine’s Department of Medicine, is a medical oncologist at the B.C. Cancer Agency specializing in gastrointestinal cancer. Through his work at the BC Cancer Agency, and as co-investigator of the clinical research initiative known as Personalized OncoGenomics (or POG), Dr. Lim is helping to revolutionize our understanding of cancer diagnosis, while seeking to pioneer a new — and personalized — approach to treating cancer. Dr. Lim is also passionate about training the next generation of physicians, serving as the director of UBC’s Medical Oncology Residency Program.
Dr. Jamie Feng, MD, FRCPC
Jamie Feng (he/him) is a medical oncologist at BC Cancer – Vancouver, where he treats patients with thoracic malignancies and sarcoma. He received his medical degree from the University of Calgary in 2017. He completed his residency in internal medicine at Memorial University of Newfoundland, where he also began a Master of Science in Clinical Epidemiology. He then completed residency training in medical oncology at the University of British Columbia in 2022, followed by a clinical fellowship in thoracic medical oncology at Princess Margaret Cancer Centre in Toronto. Dr. Feng’s research focuses on prognostic and predictive biomarkers in non-small cell lung cancer, with an emphasis on rare molecular subtypes with targetable alterations.
Dr. Kasmintan Schrader, MBBC, FRCPC, PhD, DABMG
Dr. Kasmintan Schrader received her medical degree from the University of Melbourne (2003), and completed her residency in Medical Genetics at the University of British Columbia, Canada. Dr Schrader undertook the Royal College of Physicians and Surgeons of Canada Clinician Investigator Program to undertake graduate studies in the Department of Pathology and Laboratory Medicine to investigate the association between germline mutations in CDH1 and lobular breast cancer. Her PhD work evolved to include use of next-generation sequencing technology to identify Mendelian disease genes. She was subsequently awarded a Canadian Institutes of Health and Research training award to pursue her interests in using next-generation sequencing (NGS) technology to determine novel susceptibility genes in familial colon cancer as a research fellow at MSKCC.
Dr Schrader collaborates on several projects looking at return of this type of information and has the expertise to interpret the clinical significance of incidental findings beyond those primarily associated with cancer. Her clinical genetics specialist training makes her ideally positioned to consider and answer questions regarding the return of incidental genetic information identified throughout the course of massively parallel sequencing projects.
Furthermore, as co-Medical Director of the BC Cancer agency’s Provincial Hereditary Cancer Program, Dr Schrader is well-positioned to understand the impact of these findings on the public healthcare system.
Dr. Nathalie Levasseur, MD, FRCPC
Nathalie LeVasseur is an Associate Clinical Professor in the Department of Medicine, Division of Medical Oncology at the University of British Columbia in Vancouver since October 2019. She received her medical degree in 2013 and completed her internal medicine residency at the University of Ottawa. She subsequently pursued a residency in medical oncology at the University of British Columbia and served as chief resident before completing a breast cancer clinical and research fellowship at the BC Cancer Agency.
Dr. LeVasseur is the current chair of the Provincial Breast Tumour Group in BC, the lead of the Breast Cancer Clinical Trials Unit in Vancouver and serves on the CCTG IND Executive Committee and the BC Personalized Oncogenomics Steering Committee. Her research focus is in the development of personalized oncology with informative tools, genomics and transcriptomics. Additionally, Dr. LeVasseur is the primary lead for the Patient Working Group for the Personalized Oncogenomics Program and the improvement of patient outcomes and survivorship is an area of ongoing research interest.
Dr. LeVasseur is a Fellow of the Royal College of Physicians and Surgeons of Canada. She holds professional memberships with the American Society of Clinical Oncology, Canadian Association of Medical Oncology, among others. She has received academic achievement awards including a Conquer Cancer ASCO Merit Award, NOYCIA Award and a Coltman Scholars Award.
Dr. Stephen Yip, MD, PhD, FRCPC
Dr. Stephen Yip completed his combined MD-PhD training followed by four years of neurosurgical training at UBC. He switched to neuropathology and obtained his Royal College certification in 2007. He completed fellowship training in molecular neuro-oncology at Massachusetts General Hospital under the mentorship of Dr. David Louis as a RC Clinician Investigator Program fellow and molecular genetic pathology at MGH/Harvard Medical School under the supervision of Dr. John Iafrate. He is on staff at Vancouver General Hospital and BC Cancer (VCC) and practices neuropathology and molecular genetic pathology.
Dr. Steven Jones, PhD, FRS(C), FCAHS, FRCP(Edin)
Dr. Jones’ research program is firmly entrenched in genome science to better understand the complete mutational landscape of cancers. His primary aim is to help uncover the diversity of genetic and genomic events that accrue to give rise to cancers, and which also encourage their evolution and maintain their progression. His laboratory extensively analyzes Next Generation genome and transcriptome data to achieve these goals. Dr. Jones has developed a number of novel computational approaches and methodologies to this end and has provided numerous insights into cancer dynamics, potential biomarkers and therapeutic targets. A significant part of Dr. Jones research program relates to developing more precise cancer treatments by exploiting an individual’s specific cancer genome profile. His research has identified numerous epigenetic targets that have the potential to be modulated in such a way as to reverse the effects of mutations within a cancer genome. Using computational approaches, his research team has identified and refined compounds that modify epigenetic programs in cancer. His laboratory also acts as a data analysis centre for the Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC).
In 2005, Dr. Jones was identified as one of Canada's top 40 professionals under 40 by Caldwell Partners International as well as by Business in Vancouver. He has received the Spencer Award for IT innovation as well as the 2007 Medical Genetics teaching award from UBC. He is a founding director of the CIHR/MSFHR Bioinformatics Training Program as well as director of the UBC Bioinformatics Graduate Program. In 2011, he was inducted as a Fellow of the Royal Society of Canada for his contributions to Genomics and Bioinformatics, and in 2012 he was a recipient of the prestigious UBC Killam teaching prize in recognition of his contributions to graduate bioinformatic education. In May of 2014 Dr. Jones was awarded the Distinguished Achievement Award by the Faculty of Medicine at UBC and in June 2014 he became a Fellow of the Canadian Academy of Health Sciences. He was recognized by Clarivate Analytics in 2016 and 2018 as among the world’s most highly cited researchers in his field. Dr Jones was born in Wales and trained at Bristol University, Simon Fraser University and the Sanger Institute.
Dr Jones is a founder of Ifowonco Bioinformatics Inc., Caldey Informatics Inc., Evident Genomics Inc. and Alamya Health, PBC. He is an advisor to Everyone.bio Inc., Outpost Biosciences Inc. and OncoInnovations Inc. He has received travel funding for speaking engagements from Illumina Inc. and Oxford Nanopore Technologies PLC.
Dr. Dean Regier, BA (High Hons), MA, PhD
Dr. Dean Regier is a Senior Scientist at the BC Cancer Research Institute, Associate Professor in the School of Population and Public Health at the University of British Columbia (UBC), and Director of the Academy of Translational Medicine (ATM) in UBC’s Faculty of Medicine. An internationally recognized health economist specializing in translational medicine and regulatory science, he leads the Regulatory Science Lab (RSL), which advances learning healthcare systems and develops policies to accelerate access to safe, effective, and cost-effective care. His research emphasizes patient-oriented outcomes and AI-supported real-world evidence generation, and has been instrumental in advancing equitable access to genomic technologies for Canadians—particularly in precision oncology and rare diseases.
As Director of the ATM and RSL, Dr. Regier is leading the Academy’s evolution into a world-class hub for innovation in translational medicine and regulatory science. He is expanding networks and educational initiatives in AI, regulatory affairs, regulatory science, and health economics, with the goal of strengthening UBC’s and British Columbia’s life sciences ecosystem. Through collaboration across research institutes, centres, and programs, he aims to drive global progress in translational medicine.